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Summary
PRINCIPLES: High-dose chemotherapy with subsequent
autologous stem cell transplantation (ASCT) is an import-
ant treatment option in younger patients with multiple my-
eloma (MM). We analysed the outcome of patients treated
at our institution outside the clinical trials framework and
tried to identify risk factors prognostic for survival.
List of abbreviations
ANC absolute neutrophil count
ASCT autologous stem cell transplantation
BEAM high-dose carmustine, etoposide, cytarabine and melphalan
BMI body mass index
CD34 cluster of differentiation 34
CI confidence interval
CR complete remission
CT computed tomography
Dex dexamethasone
DS Durie Salmon
EFS event free survival
HR hazard ratio
IMIDs immunomodulatory derivatives
ISS international staging system
M2 cyclophosphamide, carmustine, melphalan, prednisone
MM multiple myeloma
MR minor remission
nCR near complete remission
OS overall survival
PD progressive disease
PR partial remission
SD stable disease
Thal thalidomide
TRM treatment related mortality
VAD vincristine, adriamycin, dexamethasone
Vel bortezomib (Velcade©)
VGPR very good partial remission
METHODS: Medical histories of the patients were
screened for response, event-free survival (EFS) and over-
all survival (OS). Pre-transplant variables were analysed to
identify possible prognostic risk factors.
RESULTS: Overall, 182 ASCT were performed in 120 pa-
tients with MM from 2002 to 2007. Treatment-related mor-
tality (TRM) was 0.5%. Median EFS was 23.1 months
(95% confidence interval [CI]: 19.4–28.4) and median OS
was 49.8 months (95%CI: 43.7–not reached) in the whole
patient population. The median OS in patients who re-
ceived one ASCT was 46.4 months (95%CI: 35.2–not
reached), and 63.7 months (95%CI: 48.9–not reached) in
patients who underwent double ASCT.
Patients who already achieved a complete remission (CR)
before ASCT had a longer EFS (p = 0.016) than patients
without CR. Additionally, patients who achieved a CR after
ASCT had a longer EFS (p = 0.0061) and OS (p = 0.0024)
than patients without CR. ISS stage <III at first diagnosis
strongly correlated with improved EFS (p = 0.0006) and
OS (p <0.0001).
CONCLUSIONS: ASCT is a safe and effective treatment
mode in eligible patients with MM. TRM was below aver-
age at our institution. Achievement of CR after transplant-
ation was the most valuable predictor for improved overall
survival.
Key words: multiple myeloma; autologous
transplantation; risk factors: outcome
Introduction
High-dose chemotherapy with autologous stem cell trans-
plantation (ASCT) has been widely established as con-
solidation or salvage treatment for patients with multiple
myeloma (MM) [1–4]. In general the response after first
ASCT is being used to direct the subsequent patient treat-
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ment; application of two consecutive ASCTs within 2–6
months (so-called double or tandem ASCT) is usually re-
served for patients not achieving at least a very good partial
remission (VGPR) after the first ASCT, according to res-
ults from two randomised prospective trials [5–6]. The in-
dication and timing of high-dose chemotherapy with sub-
sequent ASCT have been matter of debate recently in light
of new active drugs, e.g., proteasome inhibitors and im-
munomodulatory derivatives (IMIDs), which are increas-
ingly incorporated into various first line treatment regi-
mens before ASCT [7–12]; the question whether high-dose
chemotherapy can be safely replaced by a non-high dose
consolidation treatment will be answered by a recently
activated international trial [13]. Furthermore, the impact
and composition of maintenance treatment after ASCT and
even allogeneic transplantation concepts are currently un-
der discussion and various prospective trials will further
define future treatment strategies for younger MM patients
[14–17]. Until these data are available and also implemen-
ted in daily practice, retrospective analyses – especially of
patients who are treated in transplantation centres outside
the clinical trials setting – are helpful in demonstrating the
current options for patients desirous of knowing their spe-
cific risks and benefits at a given institution. We started
our autologous stem cell programme in Zürich in 1988 and
have performed more than 1000 transplantations since that
time, with MM the most frequent indication for ASCT [18].
In terms of quality control we continuously evaluate our
programme’s clinical data. We have therefore analysed the
clinical course and outcome of our MM patients receiving
ASCT between 2002 and 2007 and identified possible risk
factors for survival.
Additionally, we have assessed the morbidity of our treat-
ment regimens with regard to length of hospital stay, need
for antibiotics and blood product transfusions.
Patients and methods
Patient data assessment
Records from patients with MM who received at least one
ASCT at our transplantation centre were analysed retro-
spectively on the basis of a prospective database. This ana-
lysis was approved by our local ethics committee.
The Zürich transplantation centre comprises two hospitals,
Zürich University Hospital and Triemli City Hospital,
Zürich. Data regarding myeloma stage according to the in-
ternational staging system (ISS), response to treatment be-
fore and after ASCT, event free survival (EFS) and over-
all survival (OS) were collected. Also, various parameters
such as age, gender, body mass index, time from initial dia-
gnosis to ASCT and number of ASCTs per patient were
documented if available. As quality control for our trans-
plantation programme we also collected data on the
haematological toxicity of the treatment and the supportive
care measures performed during the post-transplant period.
Treatment
Individual eligibility for ASCT was discussed in our mul-
tidisciplinary autologous transplantation board and determ-
ined in accordance with international recommendations.
Patients received either one or two ASCTs. The second
ASCT was usually performed sequentially 2–6 months
after the first ASCT (so-called double or tandem ASCT),
or, in a few patients who had initially received single
ASCT, later in their disease course in the event of pro-
gression. All patients received primary induction chemo-
therapy as chosen by the attending oncologists. For stem
cell mobilisation, either cyclophosphamide on day –12 or
vinorelbine on day –8 was given, followed by collection of
the stem cells on day 0. Additionally, patients received fil-
grastim at a dose of 10 μg/kg body weight per day from
day –4 on. Aphereses were performed at our transplanta-
tion centre until at least 4 x 106 CD34-positive cells per
kilogram body weight were collected. Subsequently stem
cells were cryopreserved and thawed immediately before
retransfusion.
Conditioning chemotherapy consisted of melphalan at a
dose of 200 mg/m2, given in two doses at days –3 and –2
or as single dose at day –2 before stem cell transplanta-
tion. Patients with reduced performance score, organ dys-
functions, e.g. renal insufficiency or age over 65 years re-
ceived a reduced dose in the range of 100–140 mg/m2
melphalan. Patients received filgrastim from day +5 on or
pegfilgrastim once on day +1 after ASCT to shorten time
to engraftment.
Response criteria
Assessment of disease response was chiefly based on ser-
ological testing because bone marrow biopsy after trans-
plantation was omitted in most of our patients. Thus, our
response assessment varied from the International Myel-
oma Working Group uniform criteria, which are currently
proposed as a new standard for response assessment [19].
Complete Remission (CR) was defined as negative im-
munofixation and disappearance of monoclonal protein in
serum and urine. Near Complete Remission (nCR) was
defined as disappearance of monoclonal protein in serum
and/or urine but persistence of positive immunofixation.
Very Good Partial Remission (VGPR) was defined as re-
duction of monoclonal protein >90% in serum. Partial Re-
mission (PR) was defined as reduction of paraprotein
≥50% in serum. Patients with Minor Response (MR)
showed a paraprotein reduction of between 25–49% re-
spectively. Stable Disease (SD) was defined as every re-
sponse between minor response and progressive disease
(PD). The latter was documented in patients who had an in-
crease in monoclonal protein ≥25% or clinical progression
after transplantation. Patients with no data available regard-
ing their response were regarded and coded as non-respon-
ders (i.e. SD).
Event free survival (EFS) was defined as time from ASCT
to the time of first recurrence after achievement of CR or
nCR, to the time of progression in non-CR patients, as
verified by serological assessment, bone marrow biopsy or
imaging, or to the time of death by any cause. Overall sur-
vival (OS) was defined as time from ASCT to the time of
death by any cause, as documented in the patient charts.
Statistics
Descriptive statistics (median and range, or counts) were
calculated for all variables. Event free and overall survival
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was calculated from the date of ASCT and censored at the
date of last follow-up. Survival curves were computed us-
ing the method of Kaplan and Meier, and compared using
the logrank test [20]. Univariate regression analysis was
performed using Cox proportional hazards regression [21].
P-values <0.05 were considered statistically significant. All
analyses were performed in the R programming language
[22].
Results
Patient demographics
Between January 2002 and December 2007 a total of 182
ASCTs were performed in 120 MM patients. Sixty-three
(53%) patients received single ASCT, and 57 (47%) pa-
tients tandem ASCTs during this period. Five (8%) of the
single-transplanted patients received a second ASCT later
in the disease course after disease progression. The median
time from diagnosis to the first ASCT was 6.24 months
(range 3.55–283.04 months). Patients predominantly re-
ceived split dose melphalan for conditioning. Only in six
cases (3%) was melphalan given as a single dose at day
–2 before ASCT. Three patients (2%) underwent haemo-
Figure 1
Kaplan–Meier analysis of the event free survival and the overall
survival of all patients. Median EFS was 23.1 months (95% CI:
19.4–28.4) and median OS was 49.8 months (95% CI: 43.7 – not
reached). ASCT, autologous stem cell transplantation.
Figure 2
Impact of the response to ASCT treatment on patients’ outcome.
(A) Event free survival, and (B) Overall survival. ASCT, autologous
stem cell transplantation; CR, complete remission; nCR, near
complete remission; VGPR, very good partial remission; PR, partial
remission.
dialysis at the time of ASCT, in two patients (2%) under-
lying amyloidosis of the kidneys had been diagnosed. Cy-
togenetics were not done routinely at our institution during
that time period, pathological findings are reported only in
five patients (4%) (three patients with del(13q), one patient
with del(13q) and t(4;14), one patient with complex aber-
rations). Patient characteristics are shown in table 1.
Pre- and post-transplant period
The patients’ peri-transplant outcome is shown in table
2. The conditioning regimens used were standard dosed
melphalan (200 mg/m2) (n = 149; 82%), reduced dosed
melphalan (100–140 mg/m2) (n = 32; 17%), and a com-
bination of bortezomib, thalidomide, dexamethasone and
BEAM (VT-Dexa-BEAM) (n = 1; 1%). Patients subse-
quently received a minimum of 2 x 106 CD34+ cells per
kilogram body weight (median 3.96 x 106 CD34+ cells/ kg;
range, 2.01 x 106 – 42.4 x 106). The median duration of
grade 4 neutropenia was 6 days (range 3–10 days) and the
median time to engraftment was 10 days (range 6–13 days).
The median duration of grade 4 thrombocytopenia was 3
days (range 0–15 days). Filgrastim was administered for a
median of 7 days (range 1–16). The median length of hos-
pital stay from the day of ASCT was 15 days (range 1–66
days). Patients received a median of 1 (range 0–8) plate-
let transfusions and a median of 0 (range 0–9) red blood
cell transfusions. Fever developed in 108 cases (59%) after
ASCT, and antibiotics for therapeutic purposes were given
in 147 cases (81%) during the post-transplant period. Bac-
terial pathogens were isolated in 58 cases (32%). Bacteria
Figure 3
Impact of ISS myeloma stage (A, B), patient age (C, D), and
melphalan dose (E, F) on patients’ outcome. (A, C, E) Event free
survival, and (B, D, F) Overall survival. ISS, international staging
system; Mel, melphalan.
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isolated were Escherichia coli (n = 20; 11%), coagulase-
negative Staphylococcus sp. (n = 14; 8%), non-haemolytic
Streptococcus sp. (n = 8; 4%), Clostridium difficile (n = 8;
4%), Pseudomonas aeruginosa (n = 3; 2%), Staphylococ-
cus aureus (n = 2; 1%), Moraxella catarrhalis (n = 2; 1%),
and others (n = 12, 6%).
Two patients (1%) died within the first 100 days after
ASCT. The first patient died at day +100 after ASCT due
to disease progression, the second patient died at day +61
after ASCT due to severe neutropenic enterocolitis and su-
perinfection with cytomegalovirus.
Response and survival
Of the 63 patients who received single ASCT, 57 (90%)
had responded (≥PR) to induction chemotherapy. Eighteen
(28%) of these patients had either VGPR or nCR, and
6 patients (10%) had already achieved CR status at the
time before ASCT. Of the 57 patients who received a true
double ASCT, 42 (74%) had at least PR after induction
chemotherapy, with 5 (9%) having achieved VGPR or nCR
and 2 (4%) having achieved CR before the first ASCT.
After high-dose chemotherapy and subsequent ASCT, the
63 single autografted patients had an overall response rate
of 82.5%, with 15 patients (24%) having achieved VGPR
or nCR and 26 (41%) CR after ASCT. The 57 patients
who received double ASCT had an overall response rate of
82.5%. Sixteen patients (28%) had achieved either VGPR
or nCR, and 21 (37%) CR after the second ASCT (table 3).
The entire patient population had a median EFS of 23.1
months (95% confidence interval (CI): 19.4–28.4) and the
median OS was 49.8 months (95% CI: 43.7 – not reached),
respectively (fig. 1). The median EFS in patients who re-
ceived single ASCT was 21.3 months (95% CI: 16.9–31.5),
and 27.2 months (95% CI: 19.9–31.9) in patients who re-
ceived double ASCT. The corresponding median OS were
46.4 months (95% CI: 35.2 – not reached) and 63.7 months
(95% CI: 48.9 – not reached), respectively.
EFS and OS correlated with the response to ASCT. Patients
achieving a CR had a significantly prolonged EFS com-
pared to patients with less than PR (HR: 2.38; 95% CI:
1.19–4.75; p = 0.014), and patients achieving a CR also
had a significantly prolonged OS compared to patients with
PR (HR: 2.5; 95% CI: 1.12–5.61; p = 0.026) or less than
PR (HR: 3.77; 95% CI: 1.4–10.19; p = 0.009) (fig. 2a and
2b). The achievement of CR was not significantly better
than achieving nCR or VGPR regarding EFS (HR: 1.67;
95% CI: 0.96–2.9; p = 0.07) and OS (HR: 1.72; 95% CI:
0.76–3.89; p = 0.2).
Patients with disease stage I or II according to the Interna-
tional Staging System (ISS) at diagnosis had a better out-
come than patients with MM stage III. The median EFS
in the former was 28.4 months (95% CI: 22.8–40.2) and
13.7 months (95% CI: 10.1–25.0) in the latter patients (HR:
1.57; 95% CI: 1.2–2.04; p = 0.0006). The corresponding
median OS was 61.1 months (95% CI: 49.8 – not reached)
for patients with ISS I or II and 33.1 months (95% CI:
27.6–46.4) for patients with ISS III (HR: 2.31; 95% CI:
1.6–3.35; p <0.0001) respectively (fig. 3a and 3b).
Age was not associated with EFS (HR: 0.86; 95% CI:
0.48−1.55; p = 0.62) or OS (HR: 0.65; 95% CI: 0.23−1.83;
p = 0.41) (fig. 3c and 3d).
Patients who received standard dose melphalan showed
a trend towards improved EFS (HR: 1.63; 95% CI:
0.96−2.75; p = 0.07) and OS (HR: 1.99; 95% CI:
0.94−4.22; p = 0.07) compared to patients who received re-
duced dose melphalan (fig. 3e and 3f).
Risk factor analysis
By univariate analysis, achievement of a CR before ASCT
correlated with better EFS compared with any other re-
sponse (p = 0.016), without impacting on OS (p = 0.21).
Also, CR after ASCT was associated with improved EFS
(p = 0.006) and OS (p = 0.0024) compared with any other
response. In the subgroup analysis, the achievement of CR
after ASCT was associated with better OS especially com-
pared to PR (p = 0.026) and responses less than PR (p =
0.009).
Other parameters significantly associated with a better EFS
were paraprotein levels of less than 5 g/dL at diagnosis (p
= 0.007), a time of 6–12 months from diagnosis to ASCT
compared with earlier transplantation (p = 0.042), and MM
stage of less than III according to ISS (p = 0.0006). The lat-
ter parameter was also significantly linked with better OS
(p <0.0001) (table 4).
Discussion
In the present analysis we observed that ASCTs performed
for MM at our centre results in high response rates of over
80% in single and in double transplanted patients. Com-
pared to available data in the literature, the procedure-re-
lated mortality during the years 2002 and 2007 was very
low with 0.5% [23]. A CR after ASCT and ISS stage of
less than III were the best predictors for prolonged surviv-
al. Age was not associated with a worse outcome in selec-
ted patients eligible for ASCT.
We were able to document a median survival of 49.8
months from the first ASCT in our patients. Separately
analysed by the number of ASCTs, the median survival
was 46.4 months for single-transplanted patients, and 63.7
months for double-transplanted patients respectively.
These results are in accordance with other published out-
come analyses [5, 24–26]. In general, only patients who do
not achieve at least a VGPR after the first ASCT might be-
nefit from a double ASCT [5–6]. Following this assump-
tion, chiefly patients with an insufficient response pro-
ceeded to a second ASCT at our centre.
We showed that patient survival correlates with the re-
sponse achieved after ASCT. Patients who achieved only a
PR or less than PR had a significantly shorter OS compared
to patients achieving a CR. On the other hand, CR did not
result in a significantly longer OS compared to the patient
subgroup achieving nCR or VGPR. This result is remark-
able considering that our patient number was rather small
and usually only studies with large patient numbers were
able to link survival with response status achieved after
treatment. A similar association of patient survival with CR
after ASCT was reported recently in a subgroup analysis of
more than 750 patients treated within the GEM2000 pro-
tocol, where the quality of response to induction therapy
had indeed a positive impact on the quality of the response
to ASCT, but without impacting on survival as impress-
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ively as the post-transplant response status [27]. The su-
periority of VGPR compared with PR after ASCT was
demonstrated by an analysis of the IFM-99 trials [28]. We
also found a significant impact of CR on patient survival,
but we cannot confirm this observation for patients with
nCR or VGPR after ASCT, most probably because of small
Table 1: Patient characteristics.
Parameter Patients
N = 120 (100%)
Age
<65 years – no. (%)
≥65 years – no. (%)
Median – yr
Range – yr
101 (84)
19 (16)
56.3
28.5–75.2
Gender
Male – no. (%)
Female – no. (%)
74 (62)
46 (38)
BMI before ASCT
Median – kg/m²
Range – kg/m²
25.2
16.76–38.64
Myeloma type
IgG – no. (%)
IgA – no. (%)
IgM – no. (%)
Bence Jones – no. (%)
Non secretory – no. (%)
Plasma cell leukaemia – no. (%)
64 (53)
25 (21)
1 (1)
25 (21)
2 (2)
3 (2)
Myeloma stage (DS)
I – no. (%)
II – no. (%)
III – no. (%)
Data missing – no. (%)
15 (13)
28 (23)
74 (62)
3 (2)
Myeloma stage (ISS)
I – no. (%)
II – no. (%)
III – no. (%)
Data missing – no. (%)
29 (24)
32 (27)
28 (23)
31 (26)
Number of ASCT received
1 – no. (%)
2 – no. (%)
58 (53)
62 (47)
Time from diagnosis to 1. ASCT
Median – months
Range – months
6.24
3.55–283
β2-Microglobulin levels at diagnosis
<3.5 mg/l – no. (%)
≥3.5 mg/l – no. (%)
Data missing – no. (%)
Median – mg/l
Range – mg/l
37 (31)
34 (28)
49 (41)
3.38
0.88–82.5
Paraprotein levels at diagnosis
<5 g/dl – no. (%)
≥5 g/dl – no. (%)
Data missing – no. (%)
Median – g/dl
Range – g/dl
43 (81)
22 (18)
55 (46)
3.52
0.1–14.3
Albumin levels at diagnosis
<3.5 g/dl – no. (%)
≥3.5 g/dl – no. (%)
Data missing – no. (%)
Median – g/dl
Range – g/dl
28 (23)
42 (35)
50 (42)
3.66
2.4–4.94
Previous chemotherapy regimens
VAD – no. (%)
Seq. VAD and M2 – no. (%)
Seq. melphalan and VAD – no. (%)
Dex monotherapy – no. (%)
ThalDex – no. (%)
Seq. Thal and Vel – no. (%)
Seq. VAD and Thal – no. (%)
Seq. VAD and Vel – no. (%)
≥3 regimens (incl. new drugs) – no. (%)
89 (74)
8 (7)
1 (1)
1 (1)
10 (8)
3 (2)
2 (2)
1 (1)
5 (4)
ASCT, autologous stem cell transplantation; BMI, body mass index; ASCT, autologous stem cell transplantation; DS, Durie-Salmon; ISS, international staging system; VAD,
vincristine, adriamycin, dexamethasone; M2, cyclophosphamide, carmustine, melphalan, prednisone; Dex, dexamethasone; Thal, thalidomide; Vel, bortezomib (velcade©).
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patient numbers. However, CR was not superior to nCR
or VGPR in our patient cohort, and in our view this find-
ing supports the general recommendation to omit a second
ASCT in patients who achieve at least a VGPR after first
ASCT.
We transplanted a very heterogeneous patient cohort with
MM at our transplantation centre. Notably, a few selected
high-risk patients with co-morbidities such as renal insuf-
ficiency or light chain amyloidosis were also treated and
a substantial subset of patients (16%) were aged over 65
years. Patients were considered transplantable if they were
biologically fit and judged able to tolerate high dose ther-
apy by the attending physician and our regular stem cell
transplantation board. The dose of melphalan was individu-
ally adjusted according to physical status and organ func-
tion. This heterogeneity of the patient collective is reflected
in the trend to prolonged EFS and OS in patients receiv-
ing standard dose melphalan for conditioning compared to
patients with presence of risk factors, whose melphalan
dose was reduced. One interesting finding of this analysis
is that elderly patients did not have, in general, a worse out-
come than younger patients. The fact that EFS was posit-
ively influenced by a higher melphalan dose may be par-
tially explained by a simple dose-efficacy correlation, as
higher drug doses may achieve a better treatment result
[29]. Furthermore, we observed the well known association
of initial ISS stage with patient survival. Our findings are
in accordance with other reports showing similar data [3,
30–33]. In contrast, the number of previous chemotherapy
regimens before ASCT did not affect patient outcome. This
finding may be explained by the fact that the majority
of the patients received only one regimen for induction,
Table 2: Pre- and post-transplantation variables.
Parameter Cases
(n = 182)
CD34+ cells reinfused
Median – x106 /kg
Range – x106 /kg
3.96
2.01–42.4
Conditioning regimen used
Normal dose melphalan – no. (%)
Reduced dose melphalan – no. (%)
Other regimen – no. (%)
149 (82)
32 (17)
1 (1)
Time to engraftment ≥500 ANC
Median – days
Range – days
10
6–13
Duration of neutropenia grade 4
Median – days
Range – days
6
3–10
Duration of thrombocytopenia grade 4
Median – days
Range – days
3
0–15
Red blood cell transfusions
Median – no. of transfusions
Range – no. of transfusions
0
0–9
Platelet transfusions
Median – no. of transfusions
Range – no. of transfusions
1
0–8
Duration of filgrastim treatment
Median – days
Range – days
7
1–16
Occurrence of neutropenic fever – no. (%)
Use of antibiotics – no. (%)
108 (59)
147 (81)
Hospital stay from day of ASCT
Median – days
Range – days
15
1–66
Treatment related mortality – no. (%) 1 (0.5)
CD34, cluster of differentiation 34; ASCT, autologous stem cell transplantation; ANC, absolute neutrophil count.
Table 3: Response rates before and after ASCT.
Response Status before ASCT in single-transplanted patients
(n = 63)
Status after ASCT in single transplanted patients
(n = 63)
CR – no. (%)
VGPR & nCR – no. (%)
PR – no. (%)
< PR – no. (%)
6 (10)
18 (28)
33 (52)
6 (10)
26 (41)
15 (24)
11 (17.5)
11 (17.5)
Response Status before 1. ASCT in double transplanted
patients (n = 57)
Status after 2. ASCT in double transplanted
patients (n = 57)
CR – no. (%)
VGPR & nCR – no. (%)
PR – no. (%)
< PR – no. (%)
2 (4)
5 (9)
35 (61)
15 (26)
21 (37)
16 (28)
10 (17.5)
10 (17.5)
ASCT, autologous stem cell transplantation; CR, complete remission; VGPR, very good partial remission; nCR, near complete remission; PR, partial remission.
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mainly VAD, and that most patients with insufficient re-
sponse could be “rescued” by a second regimen, either by
using combination chemotherapy (M2 protocol) initially or
bortezomib and IMIDs during the last years of the obser-
vation period. Finally, we did not find a statistically signi-
ficant impact of time between diagnosis and first ASCT on
overall survival.
The main limitation of this analysis is the limited patient
number. Additionally, patients were treated outside the
framework of a controlled clinical trial and differed consid-
erably regarding number and duration of preceding treat-
ment regimens, induction treatment, and risk factor profile.
The data presented here represent a “real-life” transplanta-
tion experience, a scenario that is applicable to the majority
of patients. These results are free from possible selection
bias created by entrance criteria of clinical studies, and the
conclusions reached by an analysis such as ours have their
impact on daily practice and on communication with pa-
tients. The main goal of our efforts remains the continuous
improvement in patient care we aim to achieve by monitor-
ing and analysing treatment outcome.
In conclusion, ASCT is a very safe and effective treatment
option for eligible patients with MM. Treatment-related
mortality is very low. Older patients with good perform-
ance status also benefit from an ASCT. Achievement of
a CR before ASCT is a predictor for better EFS, and CR
status after ASCT remains the best predictor for a pro-
longed OS and may spare the patients multiple ASCTs.
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